Immunosenescence: Influenza vaccination and the elderly

Current Opinion in Immunology

Volumn 29, Issue 1, 2014, Pages 38-42

  Haq, Kamran ^a   McElhaney, Janet E ^a  

^a Advanced Medical Research Institute of Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUZONE HD; INFLUENZA VACCINE; MATRIX M; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; AGE DISTRIBUTION; AGING; ANTIBODY RESPONSE; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ELDERLY CARE; HUMAN; IMMUNE AGING; IMMUNE RESPONSE; IMMUNNOSENESCENCE; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; LYMPHOCYTE FUNCTION; MOLECULAR DYNAMICS; NONHUMAN; REVIEW; SENESCENCE; T LYMPHOCYTE; VIRUS LIKE AGENT; VIRUS STRAIN; AGED; ANIMAL; CELL AGING; IMMUNOLOGY; INFLAMMATION; INFLUENZA, HUMAN;

ADJUVANTS, IMMUNOLOGIC; AGED; ANIMALS; CELL AGING; HUMANS; INFLAMMATION; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84900435086     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.03.008     Document Type: Review

References (41)

1. UN Population Division World Population Ageing 1950-2050 2002, United Nations, New York. http://www.un.org/esa/population/publications/worldaging19502050.
2. Thomas-Crusells J., McElhaney J.E., Aguado M.T. Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization. Vaccine 2012, 30:6007-6012.
3. Franceschi C., Capri M., Monti D., Giunta S., Olivieri F., Sevini F., Panourgia M.P., Invidia L., Celani L., Scurti M., et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007, 128:92-105.
4. Solana R., Tarazona R., Gayoso I., Lesur O., Dupuis G., Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 2012, 24:331-341.
5. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-1169.
6. Pawelec G., Larbi A., Derhovanessian E. Senescence of the human immune system. J Comp Pathol 2010, 142(Suppl):S39-S44.
7. Staras S.A., Dollard S.C., Radford K.W., Flanders W.D., Pass R.F., Cannon M.J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006, 43:1143-1151.
8. Wang G.C., Kao W.H., Murakami P., Xue Q.L., Chiou R.B., Detrick B., McDyer J.F., Semba R.D., Casolaro V., Walston J.D., et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol 2010, 171:1144-1152.
9. Bartlett D.B., Firth C.M., Phillips A.C., Moss P., Baylis D., Syddall H., Sayer A.A., Cooper C., Lord J.M. The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection. Aging Cell 2012, 11:912-915.
10. Centers for Disease Control and Prevention CDC Home 2013. Vaccines for Older Adults (60 Years or Older) 2013, http://www.cdc.gov/vaccines/adults/rec-vac/older-adults.html.
11. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
12. Beyer W.E., McElhaney J.E., Smith D.J., Monto A.S., Nguyen-Van-Tam J.S., Osterhaus A.D. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013, 31:6030-6033.
13. McElhaney J.E. Influenza vaccine responses in older adults. Ageing Res Rev 2011, 10:379-388.
14. McElhaney J.E., Coler R.N., Baldwin S.L. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines 2013, 12:759-766.
15. Shahid Z., Kleppinger A., Gentleman B., Falsey A.R., McElhaney J.E. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010, 28:6145-6151.
16. Wagar L.E., Gentleman B., Pircher H., McElhaney J.E., Watts T.H. Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response. PLoS One 2011, 6. 10.1371/journal.pone.0023698.
17. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., Lambkin-Williams R., Gilbert A., Oxford J., Nicholas B., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280.
18. Sridhar S., Begom S., Bermingham A., Hoschler K., Adamson W., Carman W., Bean T., Barclay W., Deeks J.J., Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013, 19:1305-1312.
19. Manzoli L., Ioannidis J.P., Flacco M.E., De Vito C., Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother 2012, 8:851-862.
20. McElhaney J.E., Beran J., Devaster J.M., Esen M., Launay O., Leroux-Roels G., Ruiz-Palacios G.M., van Essen G.A., Caplanusi A., Claeys C., et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013, 13:485-496.
21. Kanekiyo M., Wei C.J., Yassine H.M., McTamney P.M., Boyington J.C., Whittle J.R.R., Rao S.S., Kong W.-P., Wang L., Nabel G.J. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499:102-106.
22. Lee Y.T., Kim K.H., Ko E.J., Lee Y.N., Kim M.C., Kwon Y.M., Tang Y., Cho M.K., Lee Y.J., Kang S.M. New vaccines against influenza virus. Clin Exp Vaccine Res 2014, 3:12-28.
23. Sanofi Pasteur Sanofi Pasteur's Fluzone high-dose vaccine significantly more effective than standard dose Fluzone vaccine in preventing influenza in adults 2013, August 26, http://www.sanofipasteur.com/en/articles/.
24. DiazGranados C.A., Dunning A.J., Jordanov E., Landolfi V., Denis M., Talbot H.K. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013, 31:861-866.
25. ®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. Vaccine 2013, 10.1016/j.vaccine.2013.09.074.
26. Cate T.R., Rayford Y., Niño D., Winokur P., Brady R., Belshe R., Chen W., Atmar R.L., Couch R.B. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2079.
27. Principi N., Esposito S. Adjuvanted influenza vaccines. Hum Vaccin Immunother 2012, 8:59-66.
28. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med 2013, 19:1597-1608.
29. ®-adjuvanted influenza vaccine in older adults. Infect Chemother 2013, 45:159-174.
30. Van Buynder P.G., Konrad S., Van Buynder J.L., Brodkin E., Krajden M., Ramler G., Bigham M. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013, 31:6122-6128.
31. Mannino S., Villa M., Apolone G., Weiss N.S., Groth N., Aquino I., Boldori L., Caramaschi F., Gattinoni A., Malchiodi G., et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012, 176:527-533.
32. Rümke H.C., Richardus J.H., Rombo L., Pauksens K., Plaßmann G., Durand C., Devaster J.-M., Dewé W., Oostvogels L. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 2013, 13. 10.1186/1471-2334-13-348.
33. Magnusson S.E., Reimer J.M., Karlsson K.H., Lilja L., Bengtsson K.L., Stertman L. Immune enhancing properties of the novel Matrix-MTM adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 2013, 31:1725-1733.
34. Carroll T.D., Matzinger S.R., Barry P.A., McChesney M.B., Fairman J., Miller C.J. Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/DNA adjuvant. J Infect Dis 2014, 209:24-33.
35. Schreibelt G., Benitez-Ribas D., Schuurhuis D., Lambeck A.J., van Hout-Kuijer M., Schaft N., Punt C.J., Figdor C.G., Adema G.J., de Vries I.J. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 2010, 116:564-574.
36. Behzad H., Huckriede A.L., Haynes L., Gentleman B., Coyle K., Wilschut J.C., Kollmann T.R., Reed S.G., McElhaney J.E. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis 2012, 205:466-473.
37. Taylor D.N., Treanor J.J., Sheldon E.A., Johnson C., Umlauf S., Song L., Kavita U., Liu G., Tussey L., Ozer K., et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012, 30:5761-5769.
38. Koutsonanos D.G., Compans R.W., Skountzou I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol 2013, 785:121-132.
39. Arnou R., Icardi G., De Decker M., Ambrozaitis A., Kazek M.-P., Weber F., Van Damme P. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27:7304-7312.
40. Thompson C.M., Petiot E., Lennaertz A., Henry O., Kamen A.A. Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virol J 2013, 10. 10.1186/1471-2334-13-348.
41. Kang S.M., Kim M.C., Compans R.W. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012, 11:995-1007.